DANVILLE, Pa., May 10, 2024 /PRNewswire/ — Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial. The team is also the first to in the U.S. to screen for the trial. “If a patient qualifies for the…
Tag: Geisinger
FDA Grants Breakthrough Device Designation to Tempus’ Atrial Fibrillation ECG Analysis Platform, Developed in Collaboration With Geisinger
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced that the U.S. Food & Drug Administration (FDA) has granted the company Breakthrough Device Designation for its ECG Analysis Platform. The platform, developed in collaboration with Geisinger, aids clinicians in identifying patients at increased risk of developing atrial […]
Geisinger researchers find AI can predict death risk
Algorithm using echocardiogram videos of the heart outperforms other predictors of mortality DANVILLE, Pa., Feb. 9, 2021 /PRNewswire/ — Researchers at Geisinger have found that a computer algorithm developed using echocardiogram videos of the heart can predict mortality within a year. The algorithm—an example of what is known as machine learning, or artificial […]
National Institutes of Health awards Geisinger over $3.1 million for research of sudden cardiac death
DANVILLE, Pa., March 4, 2019 /PRNewswire/ — The National Institutes of Health has awarded researchers at Geisinger $3.1 million over the next five years to explore innovative approaches for early, genomics-based detection of arrhythmogenic right ventricular cardiomyopathy (ARVC). ARVC is a degenerative heart disease responsible for approximately 20 percent of sudden cardiac death in individuals […]